JP2023550148A - がん免疫治療に用いられる武装二重car-t組成物及び方法 - Google Patents
がん免疫治療に用いられる武装二重car-t組成物及び方法 Download PDFInfo
- Publication number
- JP2023550148A JP2023550148A JP2023530782A JP2023530782A JP2023550148A JP 2023550148 A JP2023550148 A JP 2023550148A JP 2023530782 A JP2023530782 A JP 2023530782A JP 2023530782 A JP2023530782 A JP 2023530782A JP 2023550148 A JP2023550148 A JP 2023550148A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- binding
- acid sequence
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
- A61K40/4204—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
- A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4256—Tumor associated carbohydrates
- A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
- A61K2239/29—Multispecific CARs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/53—Liver
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063116402P | 2020-11-20 | 2020-11-20 | |
| US63/116,402 | 2020-11-20 | ||
| US202163243486P | 2021-09-13 | 2021-09-13 | |
| US63/243,486 | 2021-09-13 | ||
| PCT/US2021/072533 WO2022109611A1 (en) | 2020-11-20 | 2021-11-19 | Armed dual car-t compositions and methods for cancer immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023550148A true JP2023550148A (ja) | 2023-11-30 |
| JP2023550148A5 JP2023550148A5 (cg-RX-API-DMAC10.html) | 2026-03-30 |
Family
ID=78918580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023530782A Pending JP2023550148A (ja) | 2020-11-20 | 2021-11-19 | がん免疫治療に用いられる武装二重car-t組成物及び方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11617767B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4247850A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023550148A (cg-RX-API-DMAC10.html) |
| TW (1) | TWI924731B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022109611A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023550148A (ja) | 2020-11-20 | 2023-11-30 | シンシア・イノベーション・インコーポレイテッド | がん免疫治療に用いられる武装二重car-t組成物及び方法 |
| CN116829587A (zh) * | 2020-12-18 | 2023-09-29 | 先声再明医药有限公司 | Her2抗体及其应用 |
| US12600801B2 (en) * | 2022-07-11 | 2026-04-14 | Fred Hutchinson Cancer Center | Single-domain antibodies that bind ROR1 |
| US20260191905A1 (en) * | 2022-12-01 | 2026-07-09 | Modernatx, Inc. | Gpc3-specific antibodies, binding domains, and related proteins and uses thereof |
| CN121666446A (zh) * | 2023-06-07 | 2026-03-13 | 新加坡科技研究局 | Gpc3嵌合抗原受体分泌 |
| JP2026519827A (ja) * | 2023-06-07 | 2026-06-18 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | Her2キメラ抗原受容体分泌 |
| WO2025140489A1 (en) * | 2023-12-29 | 2025-07-03 | Vibrant Pharma Limited | Multispecific antibodies and uses thereof |
| WO2026097068A1 (en) * | 2024-11-04 | 2026-05-07 | The General Hospital Corporation | Car-t cells secreting a cd2-binding multispecific antibody |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001008660A2 (en) * | 1999-08-02 | 2001-02-08 | The Regents Of The University Of Michigan | Targeted fiberless radiative effectors |
| JP2004507264A (ja) * | 2000-08-30 | 2004-03-11 | ザ ペン ステート リサーチ ファウンデーション | インターロイキン13のアミノ酸置換変異体 |
| WO2019157533A1 (en) * | 2018-02-12 | 2019-08-15 | The General Hospital Corporation | Chimeric antigen receptors targeting the tumor microenvironment |
| WO2020033837A1 (en) * | 2018-08-09 | 2020-02-13 | Maverick Therapeutics, Inc. | Coexpression and purification method of conditionally activated binding proteins |
| JP2020516276A (ja) * | 2017-04-14 | 2020-06-11 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍微小環境を標的にするキメラ抗原受容体t細胞 |
| CN111320694A (zh) * | 2020-02-15 | 2020-06-23 | 广西科技大学 | 一种由重链抗体的可变区组成的纳米抗体gn2及其制备方法和应用 |
| WO2020176897A1 (en) * | 2019-02-28 | 2020-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric antigen receptors and uses thereof |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| US6576232B1 (en) | 1998-04-03 | 2003-06-10 | The Penn State Research Foundation | IL13 mutants |
| US6723538B2 (en) | 1999-03-11 | 2004-04-20 | Micromet Ag | Bispecific antibody and chemokine receptor constructs |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| US8076459B2 (en) | 2003-10-16 | 2011-12-13 | Micromet Ag | Multispecfic deimmunized CD3-binders |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| BRPI0507649A (pt) | 2004-02-16 | 2007-07-10 | Micromet Ag | molécula de ligação biespecìfica, seqüência de ácido nucléico, vetor, processo para a produção da molécula de ligação biespecìfica, composição, uso da molécula de ligação biespecìfica na preparação da composição farmacêutica, e kit |
| JP5014988B2 (ja) | 2004-07-16 | 2012-08-29 | マイクロメット アクツィエン ゲゼルシャフト | 発現増強ポリペプチド |
| US20090252681A1 (en) | 2005-10-11 | 2009-10-08 | Ablynx N.V. | Nanobodies and Polypeptides Against EGFR and IGF-IR |
| WO2007042289A2 (en) | 2005-10-11 | 2007-04-19 | Ablynx N.V. | Nanobodies™ and polypeptides against egfr and igf-ir |
| DK1940461T3 (da) | 2005-11-02 | 2014-03-31 | Univ Duke | Samtidig kemoterapi og immunterapi |
| US20070264687A1 (en) | 2005-12-15 | 2007-11-15 | Min-Yuan Chou | Recombinant triplex scaffold-based polypeptides |
| WO2008119565A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific binding domain |
| EP2190861A4 (en) | 2007-08-22 | 2011-03-30 | Univ California | ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE |
| CA2735456C (en) | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| JP5676968B2 (ja) | 2010-08-12 | 2015-02-25 | キヤノン株式会社 | 画像処理装置及び画像処理方法 |
| EP3115373B1 (en) | 2010-09-08 | 2019-08-28 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
| WO2012050374A2 (en) | 2010-10-13 | 2012-04-19 | Innocell, Inc. | Immunotherapy for solid tumors |
| JP5908972B2 (ja) | 2011-04-07 | 2016-04-26 | アムジエン・インコーポレーテツド | 新規な抗原結合タンパク質 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| IN2014MN02293A (cg-RX-API-DMAC10.html) | 2012-04-20 | 2015-08-07 | Emergent Product Dev Seattle | |
| US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| KR20150029714A (ko) | 2012-07-13 | 2015-03-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 이중특이적 항체의 공-도입에 의한 car 세포의 활성 증강 |
| AU2013302696B9 (en) | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| KR20210090298A (ko) | 2012-10-30 | 2021-07-19 | 에스퍼란스 파마슈티컬스, 인코포레이티드 | 항체/약물 컨쥬게이트 및 이의 사용 방법 |
| US9562110B2 (en) | 2012-11-21 | 2017-02-07 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
| SG11201505896YA (en) | 2013-02-20 | 2015-09-29 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| IL298125A (en) | 2013-02-26 | 2023-01-01 | Memorial Sloan Kettering Cancer Center | Preparations and methods for immunotherapy |
| US20160017058A1 (en) | 2013-03-14 | 2016-01-21 | The California Institute For Biomedical Research | Bispecific antibodies and uses thereof |
| WO2014172584A1 (en) | 2013-04-17 | 2014-10-23 | Baylor College Of Medicine | IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER |
| CA2912389C (en) | 2013-06-10 | 2020-01-28 | The General Hospital Corporation D/B/A Massachusetts General Hospital | Methods and compositions for reducing immunosupression by tumor cells |
| EP2930188A1 (en) | 2014-04-13 | 2015-10-14 | Affimed Therapeutics AG | Trifunctional antigen-binding molecule |
| WO2015168474A1 (en) | 2014-04-30 | 2015-11-05 | President And Fellows Of Harvard College | Fusion proteins for treating cancer and related methods |
| EP3613433B1 (en) | 2014-05-30 | 2022-01-05 | Shanghai Henlius Biotech, Inc. | Anti-epidermal growth factor receptor (egfr) antibodies |
| CN112546230A (zh) | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| PL3177643T3 (pl) | 2014-08-04 | 2019-09-30 | F.Hoffmann-La Roche Ag | Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T |
| KR20240056629A (ko) | 2014-09-28 | 2024-04-30 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 자극성 및 비자극성 골수성 세포의 조절 |
| CA3081058C (en) | 2015-01-16 | 2024-02-20 | Academia Sinica | Linker units and their uses in configuring pharmaceutical molecules |
| EP3250611B1 (en) | 2015-01-26 | 2021-04-21 | The University of Chicago | Car t-cells recognizing cancer-specific il 13r-alpha2 |
| MA41433A (fr) | 2015-01-26 | 2017-12-05 | Baylor College Medicine | Cellules immunitaires universelles pour l'immunothérapie anticancéreuse |
| WO2016123675A1 (en) | 2015-02-05 | 2016-08-11 | The University Of Queensland | Targeting constructs for delivery of payloads |
| WO2016146894A1 (en) | 2015-03-17 | 2016-09-22 | Tilt Biotherapeutics Oy | Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto |
| WO2016154585A1 (en) * | 2015-03-26 | 2016-09-29 | Charles Sentman | Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using |
| CN104829730A (zh) | 2015-04-14 | 2015-08-12 | 苏静 | 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用 |
| EP3778640A1 (en) | 2015-05-01 | 2021-02-17 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
| ES2984656T3 (es) | 2015-05-13 | 2024-10-30 | Ablynx Nv | Polipéptidos que reclutan linfocitos T en función de la reactividad a CD3 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Egfrviii及cd3抗體構築體 |
| IL292504B2 (en) | 2015-10-20 | 2024-01-01 | Kite Pharma Inc | -methods of preparing t cells for t cell therapy |
| HUE054131T2 (hu) | 2015-11-19 | 2021-08-30 | Revitope Ltd | Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben |
| GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
| CN109071632B (zh) | 2016-02-05 | 2022-12-30 | 奥里尼斯生物科学私人有限公司 | 靶向性治疗剂及其用途 |
| JP7189019B2 (ja) | 2016-02-05 | 2022-12-13 | シティ・オブ・ホープ | 中枢神経系の癌の治療のための操作されたt細胞の投与 |
| AU2017229687A1 (en) | 2016-03-08 | 2018-09-20 | Takeda Pharmaceutical Company Limited | Inducible binding proteins and methods of use |
| US11291721B2 (en) | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| SG11201808196UA (en) | 2016-03-31 | 2018-10-30 | Neon Therapeutics Inc | Neoantigens and methods of their use |
| ES3056995T3 (en) | 2016-04-13 | 2026-02-25 | Vivia Biotech Sl | Ex vivo bite-activated t cells |
| US11596699B2 (en) | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
| EP3484455A2 (en) | 2016-07-15 | 2019-05-22 | Novartis AG | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
| WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| EP3500696A4 (en) | 2016-08-16 | 2020-04-08 | Bluebird Bio, Inc. | VARIANTS OF IL-10 ALPHA RECEPTOR HOMING ENDONUCLEASE, COMPOSITIONS AND METHODS OF USE |
| US20190262398A1 (en) | 2016-08-23 | 2019-08-29 | Bluebird Bio, Inc. | Tim3 homing endonuclease variants, compositions, and methods of use |
| KR102491752B1 (ko) | 2016-08-29 | 2023-01-26 | 싸이오서스 테라퓨틱스 엘티디. | 이중특이성 T 세포 세포 관여자(BiTE)가 보강된 아데노바이러스 |
| CN109983027A (zh) | 2016-10-20 | 2019-07-05 | 细胞基因公司 | 基于cereblon的可异二聚化嵌合抗原受体 |
| AU2017368248A1 (en) | 2016-11-30 | 2019-06-06 | Intrexon Corporation | Steroid administration and immunotherapy |
| CA3049652A1 (en) | 2017-01-10 | 2018-07-19 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
| CR20190408A (es) | 2017-02-02 | 2020-01-31 | Amgen Inc | Composición farmacéutica de bajo ph que comprende construcciones de anticuerpos que activan linfocitos t antecedentes |
| EP3615571A1 (en) | 2017-04-24 | 2020-03-04 | Ichnos Sciences SA | T cell redirecting bispecific antibodies for the treatment of egfr positive cancers |
| MA48763A (fr) | 2017-05-05 | 2020-04-08 | Amgen Inc | Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés |
| EP3635132A4 (en) | 2017-06-07 | 2021-05-26 | Intrexon Corporation | EXPRESSION OF NOVEL CELL MARKERS |
| CN111247171A (zh) | 2017-10-14 | 2020-06-05 | 西托姆克斯治疗公司 | 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法 |
| MX2020006213A (es) | 2017-12-12 | 2020-09-14 | Pionyr Immunotherapeutics Inc | Anticuerpos anti-trem2 y metodos relacionados. |
| CN120399075A (zh) | 2018-03-14 | 2025-08-01 | 诺维莫尼公司 | 抗-CD3ε抗体及其应用方法 |
| ES2914986T3 (es) | 2018-03-16 | 2022-06-20 | Univ Koeln | Derivados de Lys-C(O)-Glu sustituidos con 2-alcoxi-6-[18F]fluoronicotinoilo como sondas eficaces para la obtención de imágenes de tejidos que expresan PSMA |
| US20210128617A1 (en) | 2019-08-27 | 2021-05-06 | The Trustees Of The University Of Pennsylvania | SYNTHETIC CARS TO TREAT IL13R-alpha-2 POSITIVE HUMAN AND CANINE TUMORS |
| JP2023550148A (ja) | 2020-11-20 | 2023-11-30 | シンシア・イノベーション・インコーポレイテッド | がん免疫治療に用いられる武装二重car-t組成物及び方法 |
-
2021
- 2021-11-19 JP JP2023530782A patent/JP2023550148A/ja active Pending
- 2021-11-19 WO PCT/US2021/072533 patent/WO2022109611A1/en not_active Ceased
- 2021-11-19 US US17/531,635 patent/US11617767B2/en active Active
- 2021-11-19 EP EP21827521.2A patent/EP4247850A1/en active Pending
- 2021-11-22 TW TW110143409A patent/TWI924731B/zh active
-
2022
- 2022-12-30 US US18/148,487 patent/US12643933B2/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001008660A2 (en) * | 1999-08-02 | 2001-02-08 | The Regents Of The University Of Michigan | Targeted fiberless radiative effectors |
| JP2004507264A (ja) * | 2000-08-30 | 2004-03-11 | ザ ペン ステート リサーチ ファウンデーション | インターロイキン13のアミノ酸置換変異体 |
| JP2020516276A (ja) * | 2017-04-14 | 2020-06-11 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍微小環境を標的にするキメラ抗原受容体t細胞 |
| WO2019157533A1 (en) * | 2018-02-12 | 2019-08-15 | The General Hospital Corporation | Chimeric antigen receptors targeting the tumor microenvironment |
| WO2020033837A1 (en) * | 2018-08-09 | 2020-02-13 | Maverick Therapeutics, Inc. | Coexpression and purification method of conditionally activated binding proteins |
| WO2020176897A1 (en) * | 2019-02-28 | 2020-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric antigen receptors and uses thereof |
| CN111320694A (zh) * | 2020-02-15 | 2020-06-23 | 广西科技大学 | 一种由重链抗体的可变区组成的纳米抗体gn2及其制备方法和应用 |
Non-Patent Citations (5)
| Title |
|---|
| ANTIBODIES, vol. 8, 13, JPN5024006248, 2019, ISSN: 0005855788 * |
| IMMNOLOGICAL REVIEWS, vol. 290, no. 1, JPN5024006246, 2019, pages 60 - 84, ISSN: 0005855786 * |
| MOLECULAR THERAPY, vol. 27, no. 7, JPN5024006249, 2019, pages 1275 - 1285, ISSN: 0005855784 * |
| NATURE BIOTECHNOLOGY, vol. 37, no. 9, JPN5024006245, 2019, pages 1049 - 1058, ISSN: 0005855785 * |
| ONCOIMMUNOLOGY, vol. 7, JPN5024006247, 2018, pages 1377874, ISSN: 0005855787 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US12643933B2 (en) | 2026-06-02 |
| US20220160766A1 (en) | 2022-05-26 |
| EP4247850A1 (en) | 2023-09-27 |
| US11617767B2 (en) | 2023-04-04 |
| TW202237649A (zh) | 2022-10-01 |
| US20230277592A1 (en) | 2023-09-07 |
| WO2022109611A1 (en) | 2022-05-27 |
| TWI924731B (zh) | 2026-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11617767B2 (en) | Armed dual CAR-T compositions and methods for cancer immunotherapy | |
| Lai et al. | Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity | |
| TWI728309B (zh) | 一種結合bcma的嵌合抗原受體(car)及其應用 | |
| TWI728308B (zh) | 一種結合bcma的嵌合抗原受體(car)及其應用 | |
| Moeller et al. | Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection | |
| JP7560882B2 (ja) | 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法 | |
| JP7198670B2 (ja) | 免疫調整性il2r融合タンパク質およびその使用 | |
| JP6420776B2 (ja) | 免疫療法のためのエンゲージャー細胞 | |
| AU2017216213B2 (en) | Engineered antigen presenting cells and uses thereof | |
| EP3256496B1 (en) | Chimeric antigen receptors | |
| CA3125302A1 (en) | Methods and compositions to improve the safety and efficacy of cellular therapies | |
| KR20180095511A (ko) | 표적화된 암 요법 | |
| WO2017219936A1 (zh) | 一种高效稳定表达激活型抗体的car-t细胞及其用途 | |
| EP3765078A1 (en) | Anti-gucy2c chimeric antigen receptor compositions and methods | |
| CN113056284A (zh) | 通过肿瘤内和/或静脉内施用编码4-1bbl(cd137l)和/或cd40l的重组mva治疗癌症的疗法 | |
| Shabaneh et al. | Safety switch optimization enhances antibody-mediated elimination of CAR T cells | |
| US20230399402A1 (en) | Hla class ii-restricted tcrs against the kras g12>v activating mutation | |
| EP4370541A1 (en) | Engineered t cell receptors fused to binding domains from antibodies | |
| WO2024119769A1 (zh) | 增强向肿瘤部位浸润能力的car-nk细胞制备及应用 | |
| JP2025106309A (ja) | キメラ抗原受容体構築物およびcar-t細胞におけるそれらの使用 | |
| KR102842684B1 (ko) | 향상된 t-세포 수용체 star 및 이의 적용 | |
| JP2022516710A (ja) | Car t細胞の方法及び構築物 | |
| CN116917328A (zh) | 用于癌症免疫治疗的武装双car-t组合物和方法 | |
| CN121794286A (zh) | 假型化的病毒颗粒、包含假型化的病毒颗粒的组合物及其用途 | |
| HK40105226A (en) | Armed dual car-t compositions and methods for cancer immunotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241119 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241119 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251021 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260116 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20260319 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260512 |